MedTrace Logo

A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

NCT06828341 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-02-14

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if allogeneic CAR-T cells can treat patients with advanced gliomas. The main questions it aims to answer are:

Evaluate the safety of allogeneic CAR-T cells in the treatment of advanced gliomas.

To evaluate the effectiveness of allogeneic CAR-T cells in the treatment of advanced gliomas and to study its immunological properties in patients.

Conditions

Interventions

BIOLOGICAL

CAR-T

allogeneic CAR-T targeting CD70 that cultured from heathy adults.

Sponsors & Collaborators

  • Nanjing Kanghe Cell Gene Engineering Research Institute Co., Ltd.

    collaborator UNKNOWN

  • JIANG LONGWEI

    lead OTHER

Principal Investigators

  • Jia Shaochang, doctor · Jinling Hospital, China

  • GUO ZHIGANG, doctor · Nanjing Normal University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-13
Primary Completion
2024-07-06
Completion
2026-06-30

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06828341 on ClinicalTrials.gov